Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis
- PMID: 30519877
- PMCID: PMC7102358
- DOI: 10.1007/s11427-018-9385-3
Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis
Abstract
Fulminant myocarditis is primarily caused by infection with any number of a variety of viruses. It arises quickly, progresses rapidly, and may lead to severe heart failure or circulatory failure presenting as rapid-onset hypotension and cardiogenic shock, with mortality rates as high as 50%-70%. Most importantly, there are no treatment options, guidelines or an expert consensus statement. Here, we provide the first expert consensus, the Chinese Society of Cardiology Expert Consensus Statement on the Diagnosis and Treatment of Fulminant Myocarditis, based on data from our recent clinical trial (NCT03268642). In this statement, we describe the clinical features and diagnostic criteria of fulminant myocarditis, and importantly, for the first time, we describe a new treatment regimen termed life support-based comprehensive treatment regimen. The core content of this treatment regimen includes (i) mechanical life support (applications of mechanical respirators and circulatory support systems, including intraaortic balloon pump and extracorporeal membrane oxygenation, (ii) immunological modulation by using sufficient doses of glucocorticoid, immunoglobulin and (iii) antiviral reagents using neuraminidase inhibitor. The proper application of this treatment regimen may and has helped to save the lives of many patients with fulminant myocarditis.
Keywords: adult fulminant myocarditis; cardiogenic shock; diagnosis and treatment; expert consensus; life support-based comprehensive treatment regimen; mechanical circulatory support.
References
-
- Abdel-Aty H., Boyé P., Zagrosek A., Wassmuth R., Kumar A., Messroghli D., Bock P., Dietz R., Friedrich M.G., Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis. J Am Coll Cardiol. 2005;45:1815–1822. doi: 10.1016/j.jacc.2004.11.069. - DOI - PubMed
-
- Al-Khatib S.M., Stevenson W.G., Ackerman M.J., Bryant W.J., Callans D.J., Curtis A.B., Deal B.J., Dickfeld T., Field M.E., Fonarow G.C., et al. Circulation. 2018. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. - PubMed
-
- Ammirati E., Cipriani M., Lilliu M., Sormani P., Varrenti M., Raineri C., Petrella D., Garascia A., Pedrotti P., Roghi A., et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation. 2017;136:529–545. doi: 10.1161/CIRCULATIONAHA.117.026386. - DOI - PubMed
-
- Ammirati E., Moroni F., Sormani P., Peritore A., Milazzo A., Quattrocchi G., Cipriani M., Oliva F., Giannattasio C., Frigerio M., et al. Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol. 2017;231:216–221. doi: 10.1016/j.ijcard.2016.11.282. - DOI - PubMed
-
- Asaumi Y., Yasuda S., Morii I., Kakuchi H., Otsuka Y., Kawamura A., Sasako Y., Nakatani T., Nonogi H., Miyazaki S. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26:2185–2192. doi: 10.1093/eurheartj/ehi411. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
